Intramuscular Electrical Stimulation for the Treatment of Trigger Points in Patients With Migraine

Overview

The goal of this single-case experimental study is to investigate the effects of intramuscular electrical stimulation for the treatment of trigger points on reducing the frequency of headaches in a small sample of patients with chronic migraine. Additionally, this study seeks to investigate the effects of intramuscular electrical stimulation to trigger points on reducing the overall headache intensity, impact and disability using research validated questionnaires.Intramuscular electrical stimulation is a treatment that uses needles to deliver electrical current into muscles, or trigger points, for reducing pain and improving function. Trigger points are painful spots within taut bands of muscle that produce pain when pressure is applied or spontaneously. Participants will be included if they have at least a 6-month history of chronic migraine headache. Due to the nature of the single case experimental design study, participants will each serve as their own controls and be randomized to various baseline measures where they will record headaches and symptoms using an electronic headache diary. During the intervention phase, participants will receive dry needling treatment with intramuscular electrical stimulation, and will continue recording in the electronic headache diary and complete all self reported outcome measures at the final treatment session.

This study will recruit four participants with chronic migraine, in a non-concurrent manner. A non-concurrent multiple baseline line, A-B design will be implemented. Patients being referred for rehabilitation services to Wentworth Douglass Hospital Outpatient Physical Therapy Department with a diagnosis of migraine or headache will be screened for eligibility. Initial consultation for study eligibility will be by phone using a brief screening tool. Participants who preliminarily meet the eligibility criteria and are willing to participate in the study will be scheduled for the initial evaluation. In this study participants will be involved in two separate phases, a baseline phase and intervention phase. Before the clinical measurements or objective examination procedures are carried out, participants who are eligible based on pre-screening criteria, must sign the informed consent for study participation if willing to participate. Once signed, clinical examination tests will be carried out to determine full eligibility. All participants will undergo the following objective measures; 1. Manual examination for trigger points assessed by palpation 2. Pressure pain threshold will be assessed in the location of the trigger points using an analogue algometer (Force Dial FDK 20, Wagner Instruments, Greenwich. Connecticut) 3. Cervical spine active range of motion will be measured using a standard universal goniometer for cervical rotation, and a standard inclinometer for all other motions 4. A neurological examination will be performed consisting of screening of cranial nerves, deep tendon reflex testing; dermatome sensation testing; and myotome testing, except for the C1-C4 levels which are difficult to assess clinically via manual muscle testing 5. Segmental mobility will be tested using a lateral gliding and segmental side- bending maneuvers 6. Flexion rotation test will be performed bilaterally to assess for pain provocation, mobility of the upper cervical spine and to further rule out secondary causes of headache 7. Ligamentous safety tests to assess the alar and transverse ligaments will be assessed including the side-bending stress test and anterior shear test. 8. Craniocervical flexion test will be used to assess function of the deep neck flexors Fully eligible participants will then be randomized to one of four baseline tiers using an online randomization tool. The first tier will include 4 weeks (28 days) of baseline measures (phase A), followed by 5 weeks of treatment and symptom monitoring (phase B); the second tier will include 5 weeks (35 days) of baseline measures, followed by 5 weeks of treatment and symptom monitoring (phase B); the third tier will include 6 weeks (42 days) of baseline measure, followed by 5 weeks for treatment and symptom monitoring; and the fourth tier will include 7 weeks (49 days) of baseline measure, followed by 5 weeks for treatment and symptom monitoring. During the intervention phase, participants will receive five sessions of dry needling treatment with intramuscular electrical stimulation, one session per week for 5 weeks total. Sterilized disposable stainless-steel needles will be used and will include one standard size, .30 mm x 50 mm APS needle (Agupunt, Spain). Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi and obliquus capitis inferior. Trigger points will be treated on the side of headache or bilaterally if trigger points are present and coincide with headache. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device, ITO ES-160 electro-acupuncture unit (manufactured by ITO Co, Ltd, Tokyo, Japan). Parameters for electrical stimulation will be as follows; alternating frequencies of 6 hertz and 20 hertz using a symmetrical biphasic waveform will be used in place of fixed frequencies. An intensity will be chosen that will elicit a "strong but not painful" response, typically within the range of 0.5 to 6 milliamps, and pulse durations of 300 microseconds will be used. A treatment duration of fifteen minutes will be selected for electrical stimulation to trigger points.